We at MPNRF have been fielding many questions from the patient community about the Covid-19, or Coronavirus, situation. While information is still coming in and what we all know continues to emerge, we have provided a variety of credible resources from trusted sources below. The MPN research foundation will continue to monitor and keep you updated… Read More »MPN PATIENTS AND COVID-19
On May 6th, MPNRF will celebrate our 2nd annual Founder’s Day in memory of Robert (Bob) Rosen, the person who founded the MPN Research Foundation 20 years ago. May 6th is particularly special as it was Bob’s birthday, and we look forward to celebrating his legacy on this day for years to come. Bob was… Read More »THE MPN RESEARCH FOUNDATION CELEBRATES IT’S 2ND ANNUAL FOUNDER’S DAY
ASSOCIATED PRESS March 12, 2009 By Michael Rubinkam, Philadelphia Enquirer ALLENTOWN – Residents of an environmentally degraded region of eastern Pennsylvania say they’re looking forward to finally getting answers now that Congress has approved millions to study the first known cluster of a rare blood cancer. The Centers for Disease Control and Prevention will receive… Read More »RARE CANCER IN NORTHEAST PA. SUBJECT OF $5.5 MILLION STUDY
Dr. Ruben Mesa, Director, Mays Cancer Center, UT Health San Antonio, MD Anderson, offers guidance for patients with myeloproliferative neoplasms (MPNs) in dealing with the Coronavirus (Covid-19).
Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of Essential Thrombocythemia. This follows the Fast Track designation for the same drug in Myelofibrosis in August 2019. “The Fast Track designation by the FDA recognizes the need for novel therapeutics… Read More »IMAGO BIOSCIENCES GRANTED FAST TRACK DESIGNATION FOR IMG-7289 IN ESSENTIAL THROMBOCYTHEMIA
BREAKING NEWS! An anonymous donor has come forward and offered to MATCH all gifts made to the MPN Research Foundation by NEW donors all through January!! Whether your new gift is large or small, it will make a significant impact by providing funds to do what the foundation does best – fund research into Myeloproliferative Neoplasms. So, regardless if you’re a patient,… Read More »JANUARY NEW DONOR CHALLENGE
Since the discovery of driver mutations JAK2, CALR and MPPL in myeloproliferative neoplasms, the patient and caregivers effected have dreamed about a therapy that would target this mutation and stop the disease in its tracks. There have been no such epiphanies to date, but we hold out hope. This article on the evolution of cancer… Read More »INTRODUCING THE TARGETED ANTICANCER THERAPIES AND PRECISION MEDICINE IN CANCER COLLECTION
Two new clinical trials available for MPN patients Click here to learn more about current clinical trials for PV, ET, and MF patients. Vactosertib This is a 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs). Read the full description here Status: Not yet recruiting PRT543 This is a Phase 1… Read More »NEW CLINICAL TRIALS AVAILABLE FOR MPN PATIENTS
Although hydroxyurea is considered first-line therapy for essential thrombocythemia (ET) or polycythemia vera (PV) patients with a higher risk of vascular complications, some MPN patients can be resistant or intolerant to this kind of therapy. According to a study published in Blood, Pegylated interferon proved to be effective for patients with high-risk ET and PV who had previously discontinued… Read More »PEGYLATED INTERFERON BENEFITS HIGH-RISK MPNS PREVIOUSLY TREATED WITH HYDROXYUREA
As stated by the Leukaemia Foundation, Polycythemia Vera (PV) is diagnosed in an estimated 250 Australians each year. According to Associate Professor Steven Lane, the head of QIMR Berghofer’s Cancer Program and a Royal Brisbane and Women’s Hospital clinical hematologist, the current most effective drug on the market in Australia is Interferon. A long-acting version of… Read More »CALL FOR MPN DRUG TO BE APPROVED IN AUSTRALIA
